China will not include Pfizer Inc's Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug, China's Healthcare Security Administration (NHSA) said on Sunday.
Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug, China's Healthcare Security Administration said on Sunday.
Inclusion on the list means a drug is accessible via state insurance schemes, which will boost volumes but comes with the condition that manufacturers lower prices. Past rounds have seen drugmakers cut prices by as much as 62% after negotiations with officials. While the talks on Paxlovid failed, they succeeded with two other COVID-19 treatment drugs -- herbal medication Qingfei Paidu granules and Chinese drugmaker Genuine Biotech's Azvudine -- which will be included in the list's update, the regulator said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
China says talks to include Paxlovid in state health insurance failChina's Health Security Administration said on Sunday that talks to include Pfizer's Paxlovid in the latest drug list for basic state health insurance did not succeed.
Lire la suite »
WSJ News Exclusive | KKR Picking Up Manhattan Office Space Vacated by FacebookKKR is taking a big chunk of Manhattan office space being vacated by Facebook parent Meta, the latest sign that modern buildings can continue to attract tenants despite the rise of remote work and recession risks
Lire la suite »
D-FW’s newest Fortune 500 firm enters the EV battery businessCaterpillar Inc. is investing in a California company that makes lithium-ion battery packs.
Lire la suite »
Verizon shares log best six-day stretch since 2020The new year is bringing new momentum for Verizon Communications Inc.'s stock.
Lire la suite »
Chinese-made mRNA vaccine starts trial productionChina's CanSino Biologics Inc has entered 'test production phase' for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account late on Thursday.
Lire la suite »
As COVID surges in China, US begins testing more travelers | amNewYorkThe airport testing is part of the government's early warning system for detecting new variants, which began expanding recently in the wake of a COVID-19 surge in China.
Lire la suite »